Ted Simon

Ted Simon

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Toxicology in Vitro
Verified
Journal Article
Closed access
SBShannon M. Bell
Shannon M. Bell
XCXiaoqing Chang
Xiaoqing Chang
JWJohn Wambaugh
John Wambaugh
DADavid G. Allen
David G. Allen
MBMike Bartels
Mike Bartels
NKNicole Kleinstreuer
Nicole Kleinstreuer

1 July 2007 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
TSTed Simon
Ted Simon
JBJanice K. Britt
Janice K. Britt
RJRobert C. James
Robert C. James

4 November 2013 in Critical Reviews in Toxicology
Verified
Journal Article
Closed access
PDF file
RBR. A. Budinsky
R. A. Budinsky
DSD. Schrenk
D. Schrenk
TSTed Simon
Ted Simon
MBM. Van Den Berg
M. Van Den Berg
JRJohn F. Reichard
John F. Reichard
JRJ. C. Rowlands
J. C. Rowlands
Dioxins and dioxin-like compounds are tumor promoters that cause liver cancer in rats and mice. The aryl hydrocarbon receptor (AHR) has been implicated as a key component in this tumor promotion response. Despite extensive knowledge of the toxicology of dioxins, no mode of action (MOA) hypothesis for their tumorigenicity has been formally documented using the Human Relevance MOA framework developed by the International Programme on Chemical Safety (IPCS). To address this information gap, an expert panel was convened as part of a workshop on receptor-mediated liver tumorigenicity. Liver tumors induced by ligands of the AHR were assessed using data for dioxins and related chemicals as a case study. The panel proposed a MOA beginning with sustained AHR activation, eventually leading to liver tumors via a number of other processes, including increased cell proliferation of previously initiated altered hepatic foci, inhibition of intrafocal apoptosis and proliferation of oval cells. These processes have been identified and grouped as three key events within the hepatocarcinogenic MOA: (1) sustained AHR activation, (2) alterations in cellular growth and homeostasis and (3) pre-neoplastic tissue changes. These key events were identified through application of the Bradford-Hill considerations in terms of both their necessity for the apical event/adverse outcome and their human relevance. The panel identified data supporting the identification and dose–response behavior of key events, alteration of the dose–response by numerous modulating factors and data gaps that potentially impact the MOA. The current effort of applying the systematic frameworks for identifying key events and assessing human relevance to the AHR activation in the tumorigenicity of dioxins and related chemicals is novel at this time. The results should help direct future regulatory efforts and research activities aimed at better understanding the potential human cancer risks associated with dioxin exposure.

1 April 2016 in Environment International
Verified
Journal Article
Open access
NBNancy B. Beck
Nancy B. Beck
RBRichard A. Becker
Richard A. Becker
NENeeraja Erraguntla
Neeraja Erraguntla
WFWilliam H. Farland
William H. Farland
RGRoberta L. Grant
Roberta L. Grant
MDMichael L. Dourson
Michael L. Dourson
Single point estimates of human health hazard/toxicity values such as a reference dose (RfD) are generally used in chemical hazard and risk assessment programs for assessing potential risks associated with site- or use-specific exposures. The resulting point estimates are often used by risk managers for regulatory decision-making, including standard setting, determination of emission controls, and mitigation of exposures to chemical substances. Risk managers, as well as stakeholders (interested and affected parties), often have limited information regarding assumptions and uncertainty factors in numerical estimates of both hazards and risks. Further, the use of different approaches for addressing uncertainty, which vary in transparency, can lead to a lack of confidence in the scientific underpinning of regulatory decision-making. The overarching goal of this paper, which was developed from an invited participant workshop, is to offer five approaches for presenting toxicity values in a transparent manner in order to improve the understanding, consideration, and informed use of uncertainty by risk assessors, risk managers, and stakeholders. The five approaches for improving the presentation and communication of uncertainty are described using U.S. Environmental Protection Agency's (EPA's) Integrated Risk Information System (IRIS) as a case study. These approaches will ensure transparency in the documentation, development, and use of toxicity values at EPA, the Agency for Toxic Substances and Disease Registry (ATSDR), and other similar assessment programs in the public and private sector. Further empirical testing will help to inform the approaches that will work best for specific audiences and situations.

1 April 2018 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
TSTed Simon
Ted Simon

1 March 2013 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
GPGrace Patlewicz
Grace Patlewicz
TSTed Simon
Ted Simon
KGKaty Goyak
Katy Goyak
RPRichard D. Phillips
Richard D. Phillips
JRJ. Craig Rowlands
J. Craig Rowlands
RBRichard A. Becker
Richard A. Becker
Advances in high throughput and high content (HT/HC) methods such as those used in the fields of toxicogenomics, bioinformatics, and computational toxicology have the potential to improve both the efficiency and effectiveness of toxicity evaluations and risk assessments. However, prior to use, scientific confidence in these methods should be formally established. Traditional validation approaches that define relevance, reliability, sensitivity and specificity may not be readily applicable. HT/HC methods are not exact replacements for in vivo testing, and although run individually, these assays are likely to be used as a group or battery for decision making and use robotics, which may be unique in each laboratory setting. Building on the frameworks developed in the 2010 Institute of Medicine Report on Biomarkers and the OECD 2007 Report on (Q)SAR Validation, we present constructs that can be adapted to address the validation challenges of HT/HC methods. These are flexible, transparent, and require explicit specification of context and purpose of use such that scientific confidence (validation) can be defined to meet different regulatory applications. Using these constructs, we discuss how anchoring the assays and their prediction models to Adverse Outcome Pathways (AOPs) could facilitate the interpretation of results and support scientifically defensible fit-for-purpose applications.